OSRH

OSR Holdings Inc

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become the preferred pathway for bringing next-generation therapies to market. Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology.</p></p>Shares of OSR Holdings, Inc. (<a href="https://www.allpennystocks.com/stockquote/osrh" target="_blank"><strong>NASDAQ: OSRH</strong></a>) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.</p></p>The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-through of commercial royalties that BCME may collect from any future pharmaceutical partner, structured with a defined delta-recovery mechanism that allows BCME to recoup milestone differentials before royalty sharing commences.</p></p>The term sheet establishes a six-month exclusivity period during which both parties will work toward finalizing a definitive licensing agreement, subject to customary due diligence and board approvals. Under the contemplated framework, BCME would function as a strategic financial intermediary, providing capital to fund the partnering and development activities necessary to secure a global out-license with a major pharmaceutical company. This approach mirrors structured financing models deployed by specialized life sciences investors including Royalty Pharma, Blackstone Life Sciences, and RTW Investments.</p></p>According to Andreas Niethammer, incoming CEO of Vaximm AG, the term sheet represents an important milestone for advancing VXM01's development and global commercialization while allowing Vaximm to retain full ownership of its intellectual property. The structure enables the company to continue its mission of delivering innovative immunotherapies to patients worldwide with reduced dilution risk.</p></p>Tim Smith, Head of Investor Relations at OSR Holdings, emphasized that Vaximm's oral T-cell platform represents a genuinely innovative approach in oncology with potential to transform cancer treatment. The exclusivity period with BCME reflects shared commitment to maximizing the global opportunity for VXM01, positioning the asset for a major pharmaceutical partnership that could unlock its full commercial potential.</p></p>The term sheet also incorporates an optional blockchain-based royalty participation mechanism utilizing "TAC" tokens as an on-chain representation of future royalty revenue streams. Should Vaximm elect to draw development capital from the BCM Royalty Fund, a portion of VXM01 commercial royalties could be allocated to TAC token holders. If this option is not exercised, royalties would flow exclusively through the BCME pass-through structure.</p></p>Vaximm's VXM01 platform employs a proprietary oral T-cell vaccination approach using live, attenuated bacterial vectors to deliver tumor-associated antigens and induce robust cellular immune responses. The lead candidate targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications. BCME, a Switzerland-based life sciences investment entity, is currently OSR Holdings' largest shareholder.</p></p>Shares of OSRH are up 25.8% at $0.57 in Friday afternoon trading.</p> <p>Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.</p><p>View <a href='https://www.allpennystocks.com/specialreportsUS/4014/cancer-immunotherapy-microcap-soars-on-possible-major-licensing-deal'>more of this article</a> on AllPennyStocks.com.</p><p><strong>About AllPennyStocks.com Media, Inc.:</strong></p> <p>Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.</p> <p>Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.</p> <p>AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.</p> <p>Contact:</p> <p>AllPennyStocks.com Media, Inc.</p> <p>Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a></p> <p>Phone: (800) 558-4560 Ext: 101</p>

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe...

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion OSR Holdings Appoints Scientific Co-Founder...

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor...

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care OSR Holdings Signs Definitive Agreement to Acquire...